Current pharmacotherapy options for osteomyelitis: convergences, divergences and lessons to be drawn

Bibliography

• Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004;364:369-79
   PubMed Web of Science ®Google Scholar
• Cierny G, Mader JT, Pennick JJ. A clinical staging system for adult osteomyelitis. Contemp Orthop 1985;10:17-37
   Google Scholar
• Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis 2012;54:393-407
   PubMed Web of Science ®Google Scholar
• Salvana J, Rodner C, Browner BD, Chronic osteomyelitis: results obtained by an integrated team approach to management. Conn Med 2005;69:195-202
   PubMedGoogle Scholar
• Peyrani P, Allen M, Seligson D, Clinical outcomes of -steomyelitis patients infected with methicillin-resistant Staphylococcus aureus USA-300 strains. Am J Orthop (Belle Mead NJ) 2012;41:117-22
   PubMedGoogle Scholar
• Antibiotic resistance surveillance in Europe 2010. Annual report of the European Antibiotic Resistance Surveillance Network (EARS-Net) Surveillance reports-17 Nov 2011. Available from: http://www.ecdc.europa.eu
   Google Scholar
• Canton R, Akova M, Carmeli Y, European Network on Carbapenemases. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012;18:413-31
   PubMed Web of Science ®Google Scholar
• Senneville E, Melliez H, Beltrand E, Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. Clin Infect Dis 2006;42:57-62
   PubMed Web of Science ®Google Scholar
• Zuluaga AF, Galvis W, Jaimes F, Vespa O. Lack of microbiological concordance between bone and non-bone specimens in chronic osteomyelitis: an observational study. BMC Infect Dis 2002;2:8
   PubMed Web of Science ®Google Scholar
• Marschall J, Bhavan KP, Olsen MA, The impact of prebiopsy antibiotics on pathogen recovery in hematogenous vertebral osteomyelitis. Clin Infect Dis 2011;52:867-72
   PubMedGoogle Scholar
• Landersdorfer CB, Bulitta JB, Kinzig M, Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet 2009;48:89-124
   PubMed Web of Science ®Google Scholar
• Pea F. Penetration of antibacterials into bone: what do we really need to know for optimal prophylaxis and treatment of bone and joint infections? Clin Pharmacokinet 2009;48:125-7
   PubMed Web of Science ®Google Scholar
• Widmer AF, Frei R, Rajacic Z, Zimmerli W. Correlation between in vivo and in vitro efficacy of antibiotic agents against foreign body infections. J Infect Dis 1990;162:96-102
   PubMed Web of Science ®Google Scholar
• Widmer AF, Wiestner A, Frei R, Zimmerli W. Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrob Agents Chemother 1991;35:741-6
   PubMed Web of Science ®Google Scholar
• Murillo O, Domenech A, Garcia A, Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2006;50:4011-17
   PubMed Web of Science ®Google Scholar
• Mascio CT, Alder JD, Silverman JA. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother 2007;51:4255-60
   PubMed Web of Science ®Google Scholar
• Sedghizadeh PP, Kumar SK, Gorur A, Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. J Am Dent Assoc 2009;140:1259-65
   PubMed Web of Science ®Google Scholar
• Patel R. Biofilms and Antibiotic resistance. Clin Orthop Relat Res 2005;437:41-7
   PubMed Web of Science ®Google Scholar
• Norden CW, Bryant R, Palmer D, Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. South Med J 1986;79:947-51
   PubMed Web of Science ®Google Scholar
• Rybak M, Lomaestro B, Rotschafer JC, Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98
   PubMedGoogle Scholar
• Lodise TP, Patel N, Lomaestro BM, Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009;49:507-14
   PubMed Web of Science ®Google Scholar
• Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother 2009;53:4069-79
   PubMed Web of Science ®Google Scholar
• LeFrock J, Ristuccia A. Teicoplanin in the treatment of bone and joint infections: an open study. J Infect Chemother 1999;5:32-9
   PubMedGoogle Scholar
• Lemaire X, Loiez C, Valette M, Comparison of vancomycin and teicoplanin trough serum levels in patients with infected orthopedic devices: new data for old therapies. J Infect Chemother 2011;17:370-4
   PubMedGoogle Scholar
• Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:2538-44
   PubMed Web of Science ®Google Scholar
• Nannini E, Murray BE, Arias CA. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 2010;10:516-21
   PubMed Web of Science ®Google Scholar
• Traunmuller F, Schintler MV, Metzler J, Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother 2010;65:1252-7
   PubMed Web of Science ®Google Scholar
• Lefebvre M, Jacqueline C, Amador G, Efficacy of daptomycin combined with rifampicin for the treatment of experimental methicillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis. Int J Antimicrob Agents 2010;36:542-4
   PubMed Web of Science ®Google Scholar
• Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin:a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005;55:283-8
   PubMed Web of Science ®Google Scholar
• Garrigos C, Murillo O, Euba G, Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2010;54:5251-6
   PubMed Web of Science ®Google Scholar
• Parra-Ruiz J, Bravo-Molina A, Pena-Monje A, Hernandez-Quero J. Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm. J Antimicrob Chemother 2012;2682-5
   PubMedGoogle Scholar
• Burkhardt O, Kielstein JT. A simplified three-times weekly daptomycine dosing regimen for chronic hemodialysis patients. Expert Rev Anti Infect Ther 2010;8:11-14
   PubMed Web of Science ®Google Scholar
• Kielstein JT, Eugbers C, Bode-Boeger SM, Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis-a pharmacokinetic study. Nephrol Dial Transplant 2010;25:1537-41
   PubMed Web of Science ®Google Scholar
• Holtom PD, Zalavras CG, Lamp KC, Clinical experience with daptomycin treatment of foot or ankle osteomyelitis: a preliminary study. Clin Orthop Relat Res 2007;461:35-9
   PubMedGoogle Scholar
• Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med 2007;120(10 Suppl 1):S13-20
   Google Scholar
• Byren I, Rege S, Campanaro E, Two-stage revision arthroplasty with prosthetic devices undergoing of patients with osteomyelitis associated standard-of-care therapy for management and efficacy of daptomycin versus. Antimicrob Agents Chemother 2012;56:5626-32
   PubMed Web of Science ®Google Scholar
• Gallagher JC, Huntington JA, Culshaw D, Daptomycin therapy for osteomyelitis: a retrospective study. BMC Infect Dis 2012;12:133
   PubMed Web of Science ®Google Scholar
• Moenster RP, Linneman TW, Finnegan PM, McDonald JR. Daptomycin compared to vancomycin for the treatment of osteomyelitis: a single-center, retrospective cohort study. Clin Ther 2012;34:1521-7
   PubMedGoogle Scholar
• Pillai KS, Wennersten CB, Venkataraman L, Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aurous. Clin Infect Dis 2009;49:1169-74
   PubMedGoogle Scholar
• Marty FM, Yeh WW, Wennersten CB, Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006;44:595-7
   PubMed Web of Science ®Google Scholar
• Berti AD, Wergin JE, Girdaukas GG, Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics. Antimicrob Agents Chemother 2012;56:5046-53
   PubMed Web of Science ®Google Scholar
• Garrigos C, Murillo O, Lora-Tamayo J, Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant staphylococcus aurous. Antimicrob Agents Chemother 2013;57:606-10
   PubMed Web of Science ®Google Scholar
• Parra-Ruiz J, Pena-Monje A, Tomas-Jimenez C, Efficacy and safety of high dose (≥ 8 mg/kg/day) daptomycin. Enferm Infecc Microbiol Clin 2011;29:425-7
   PubMedGoogle Scholar
• Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis 2006;43:180-7
   PubMed Web of Science ®Google Scholar
• Wu VC, Wang YT, Wang CY, High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006;42:66-72
   PubMed Web of Science ®Google Scholar
• Palenzuela L, Hahn NM, Nelson RP Jr, Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 2005;40:113-16
   PubMed Web of Science ®Google Scholar
• Senneville E, Legout L, Valette M, Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006;28:1155-63
   PubMed Web of Science ®Google Scholar
• Chesi G, Colli A, Mestres CA, Multiresistant-MRSA tricuspid valve infective endocarditis with ancient osteomyelitis locus. BMC Infect Dis 2006;26:124
   Google Scholar
• Legout L, Valette M, Dezeque H, Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia? J Antimicrob Chemother 2010;65:2224-30
   PubMed Web of Science ®Google Scholar
• Gandelman K, Zhu T, Fahmi OA, Unexpected effect of rifampin on the PK of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol 2011;51:229-36
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P, Cojutti P, Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 2012;67:2034-42
   PubMed Web of Science ®Google Scholar
• Saginur R, Stdenis M, Ferris W, Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother 2006;50:55-61
   PubMed Web of Science ®Google Scholar
• Yamaoka T. The bactericidal effects of anti-MRSA agents with rifampicin and sulfamethoxazole-trimethoprim against intracellular phagocytized MRSA. J Infect Chemother 2007;13:141-6
   PubMedGoogle Scholar
• Van der Auwera P, Klastersky J, Thys JP, Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob Agents Chemother 1985;28:467-72
   PubMedGoogle Scholar
• Norden CW, Bryant R, Palmer D, Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. South Med J 1986;79:947-51
   PubMed Web of Science ®Google Scholar
• Wehrli W. Rifampin: mechanisms of action and resistance. Rev Infect Dis 1983;5(Suppl 1):407-11
   Google Scholar
• Zeller V, Dzeing-Ella A, Kitzis MD, Continuous clindamycin infusion, an innovative approach to treating bone and joint infections. Antimicrob Agents Chemother 2010;54:88-92
   PubMed Web of Science ®Google Scholar
• Nijland HM, Ruslami R, Suroto AJ, Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007;45:1001-7
   PubMed Web of Science ®Google Scholar
• Zimmerli W, Widmer A, Blatter M, Role of rifampin for treatment of orthopaedic implant-related staphylococcal infections. JAMA 1998;279:1537-41
   PubMed Web of Science ®Google Scholar
• El Helou OC, Berbari EF, Lahr BD. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis 2010;29:9617
   Google Scholar
• Senneville E, Joulie D, Legout L, Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis 2011;53:334-40
   PubMed Web of Science ®Google Scholar
• Lora-Tamayo J, Murillo O, Iribarren JA, "A Large multicenter study of methicillin-susceptible and methicillin-resistant staphylococcus aureus prosthetic joint infections managed with implant retention”. Clin Infect Dis 2013;56(2):182-94
   PubMed Web of Science ®Google Scholar
• Olson ME, Slater SR, Rupp ME, Fey PD. Rifampicin enhances activity of daptomycin and vancomycin against both a polysaccharide intercellular adhesin (PIA)- dependent and -independent Staphylococcus epidermidis biofilm. J Antimicrob Chemother 2010;65:2164-71
   PubMed Web of Science ®Google Scholar
• Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012;54:1699-709
   PubMed Web of Science ®Google Scholar
• Kandemir O, Oztuna V, Colak M, Comparison of the efficacy of tigecycline and teicoplanin in an experimental methicillin-resistant Staphylococcus aureus osteomyelitis model. J Chemother 2008;20:53-7
   PubMed Web of Science ®Google Scholar
• Yin LY, Calhoun JH, Thomas TS, Wirtz ED. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model. J Antimicrob Chemother 2009;63:357-60
   PubMed Web of Science ®Google Scholar
• Twilla JD, Gelfand MS, Cleveland KO, Usery JB. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. J Antimicrob Chemother 2011;66:2675-7
   PubMed Web of Science ®Google Scholar
• Telavancin (Vibativ) Prescribing Information. Theravance, Inc./Astellas Pharma US, Inc, South San Francisco, CA/Deerfield, IL; 2009
   Google Scholar
• Kollef MH. New Antibiotic agents for methicillin-resistant Staphylococcus aureus. Crit Care Resusc 2009;11:282-6
   PubMedGoogle Scholar
• Jacqueline C, Amador G, Caillon J, Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis. J Antimicrob Chemother 2010;65:1749-52
   PubMed Web of Science ®Google Scholar
• Atkins B, Gottlieb T. Fusidic acid in bone and joint infections. Int J Antimicrob Agents 1999;12(Suppl 2):S79-93
   Google Scholar
• Ruparelia N, Atkins BL, Hemingway J, Pristinamycin as adjunctive therapy in the management of Gram-positive multi-drug resistant organism (MDRO) osteoarticular infection. J Infect 2008;57:191-7
   PubMed Web of Science ®Google Scholar
• Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis 2009;29:127-42
   PubMed Web of Science ®Google Scholar
• Aligholi M, Emaneini M, Taherikalani M, Time-kill study and synergistic activity of cell-wall inhibitor antibiotics in combination with gentamicin against Enterococcus faecalis and Enterococcus faecium. Acta Microbiol Immunol Hung 2011;58:219-26
   PubMedGoogle Scholar
• Euba G, Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrob Agents Chemother 2009;53(6):2672-6
   PubMed Web of Science ®Google Scholar
• Berbari EF, Steckelberg JM, Osmon DR. Osteomyelitis. In: Mandell GL, editor. Principles and practice of infectious diseases. Elsevier, Philadelphia; 2005. p. 1322
   Google Scholar
• Carvalho VC, Oliveira PR, Dal-Paz K, Gram-negative osteomyelitis: clinical and microbiological profile. Braz J Infect Dis 2012;16:63-7
   PubMedGoogle Scholar
• Galanakis N, Giamarellou H, Moussas T, Dounis E. Chronic osteomyelitis caused by multi-resistant Gram-negative bacteria: evaluation of treatment with newer quinolones after prolonged follow-up. J Antimicrob Chemother 1997;39:241-6
   PubMed Web of Science ®Google Scholar
• Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother 2003;51:1261-8
   PubMed Web of Science ®Google Scholar
• Barberan J, Gomis M, Sanchez B, Cefepime in the treatment of osteomyelitis caused by Gram negative bacilli. Rev Esp Quimioter 2000;13:366-73
   PubMedGoogle Scholar
• Jauregui L, Matzke D, Scott M, Cefepime as treatment for osteomyelitis and other severe bacterial infections. J Antimicrob Chemother 1993;32(Suppl B):141-9
   PubMedGoogle Scholar
• Widmer AF, Wiestner A, Frei R, Zimmerli W. Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrob Agents Chemother 1991;35:741-6
   PubMed Web of Science ®Google Scholar
• Legout L, Senneville E, Stern R, Treatment of bone and joint infections caused by Gram-negative bacilli with a cefepime-fluoroquinolone combination. Clin Microbiol Infect 2006;12:1030-3
   PubMed Web of Science ®Google Scholar
• Tice AD. Ertapenem: a new opportunity for outpatient parenteral Antibiotic therapy. J Antimicrob Chemother 2004;53(Suppl 2):83-6
   Google Scholar
• Goswami ND, Johnson MD, Chu VH. Ertapenem for treatment of osteomyelitis: a case series. BMC Res Notes 2011;2:478
   Google Scholar
• Ferry T, Senechal A, Gagnieu MC, Prolonged subcutaneous high dose (1 g bid) of Ertapenem as salvage therapy in patients with difficult-to-treat bone and joint infection. J Infect 2012;65:579-82
   PubMed Web of Science ®Google Scholar
• Kubin CJ, Ellman TM, Phadke V, Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 2012;65:80-7
   PubMed Web of Science ®Google Scholar
• Balaji V, Jeremiah SS, Baliga PR. Polymyxins: antimicrobial susceptibility concerns and therapeutic options. Indian J Med Microbiol 2011;29:230-42
   PubMedGoogle Scholar
• Han IH, Choi BK, Nam KH, Kim SY. Bacteroides fragilis vertebral osteomyelitis complicated by percutaneous epidural adhesiolysis: a case report. Spine (Phila Pa 1976) 2013; [Epub ahead of print]
   Google Scholar
• Walter G, Kemmerer M, Kappler C, Hoffmann R. Treatment Algorithms for Chronic Osteomyelitis. Dtsch Arztebl Int 2012;109:257-64
   PubMed Web of Science ®Google Scholar
• Fraimow HS. Systemic Antibiotic therapy in osteomyelitis. Semin Plast Surg 2009;23:90-9
   PubMedGoogle Scholar
• Lipsky BA, Berendt AR, Cornia PB, 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012;54:e132-73
   PubMed Web of Science ®Google Scholar
• Senneville E, Lombart A, Beltrand E, Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study. Diabetes Care 2008;31:637-42
   PubMed Web of Science ®Google Scholar
• Venkatesan P, Lawn S, Macfarlane RM, Conservative management of osteomyelitis in the feet of diabetic patients. Diabet Med 1997;14:487-90
   PubMed Web of Science ®Google Scholar
• Senneville E, Yazdanpanah Y, Cazaubiel M, Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. J Antimicrob Chemother 2001;48:927-30
   PubMed Web of Science ®Google Scholar
• Pulcini C, Couadau T, Bernard E, Adverse effects of parenteral Antibiotic therapy for chronic bone infections. Eur J Clin Microbiol Infect Dis 2008;27:1227-32
   PubMed Web of Science ®Google Scholar
• Barbot A, Venisse N, Rayeh F, Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med 2003;29:1528-34
   PubMed Web of Science ®Google Scholar
• Conterno LO, da Silva Filho CR. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Res 2009;8:CD004439
   Google Scholar
• Norden CW, Shinners E, Niederriter K. Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus. J Infect Dis 1986;153:956-9
   PubMed Web of Science ®Google Scholar
• Wu M, von Eiff C, Al Laham N, Tsuji BT. Vancomycin and daptomycin pharmacodynamics differ against a site-directed Staphylococcus epidermidis mutant displaying the small-colony-variant phenotype. Antimicrob Agents Chemother 2009;53:3992-5
   PubMedGoogle Scholar